NASA's SpaceX Crew-13 to Advance ISS National Lab Research in…

Event summary

NASA's SpaceX Crew-13 mission, launching October 1, 2026, will support over 1,000 ISS National Lab-sponsored research projects during a six-month expedition.
Research spans biomanufacturing, regenerative medicine, physical sciences, and student-led experiments, with a focus on advancing biomedical innovation and technology development.
Key projects include neural organoid studies for Parkinson's research, cardiac spheroid growth for cardiovascular disease modeling, and protein crystallization for cancer therapeutics.
The crew will also install Voyager Technologies' Nanoracks External Laboratory (NEL), a next-generation platform for external space station experiments.

The big picture

The ISS National Lab continues to position itself as a critical hub for non-NASA research, fostering collaborations between academic institutions, private companies, and government agencies. With over 1,000 payloads delivered since 2011 and 705 peer-reviewed publications, the lab is driving significant advancements in biomedical innovation and commercial space utilization. The Crew-13 mission underscores the growing intersection of space exploration and terrestrial applications, particularly in healthcare and materials science.

What we're watching

Biotech Breakthroughs: How microgravity research will accelerate therapeutic advancements, particularly in neurodegenerative diseases and cancer treatments.
Commercial Space Utilization: Whether the ISS National Lab can sustain its role in enabling a robust low Earth orbit (LEO) economy through continued private-sector collaboration.
STEM Pipeline Development: The pace at which student-led research initiatives translate into future workforce advancements in space science and technology.